GB0909198D0 - Methods and composition for treating NF-kappa B mediated disorders - Google Patents

Methods and composition for treating NF-kappa B mediated disorders

Info

Publication number
GB0909198D0
GB0909198D0 GBGB0909198.4A GB0909198A GB0909198D0 GB 0909198 D0 GB0909198 D0 GB 0909198D0 GB 0909198 A GB0909198 A GB 0909198A GB 0909198 D0 GB0909198 D0 GB 0909198D0
Authority
GB
United Kingdom
Prior art keywords
kappa
treating
composition
methods
mediated disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0909198.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Priority to GBGB0909198.4A priority Critical patent/GB0909198D0/en
Publication of GB0909198D0 publication Critical patent/GB0909198D0/en
Priority to PCT/GB2010/001054 priority patent/WO2010136766A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GBGB0909198.4A 2009-05-28 2009-05-28 Methods and composition for treating NF-kappa B mediated disorders Ceased GB0909198D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0909198.4A GB0909198D0 (en) 2009-05-28 2009-05-28 Methods and composition for treating NF-kappa B mediated disorders
PCT/GB2010/001054 WO2010136766A2 (en) 2009-05-28 2010-05-28 Methods and compositions for treating nf-kappa b mediated disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0909198.4A GB0909198D0 (en) 2009-05-28 2009-05-28 Methods and composition for treating NF-kappa B mediated disorders

Publications (1)

Publication Number Publication Date
GB0909198D0 true GB0909198D0 (en) 2009-07-15

Family

ID=40902246

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0909198.4A Ceased GB0909198D0 (en) 2009-05-28 2009-05-28 Methods and composition for treating NF-kappa B mediated disorders

Country Status (2)

Country Link
GB (1) GB0909198D0 (en)
WO (1) WO2010136766A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115161289B (en) * 2022-03-14 2023-12-05 东南大学 A recombinant adeno-associated virus for the treatment of inflammatory diseases and its construction method and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94206C2 (en) * 2003-10-31 2011-04-26 Дзе Юніверсіті Оф Брітіш Коламбіа Bacterial virulence factors and variants of using them
WO2011007350A2 (en) * 2009-07-13 2011-01-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Immunomodulatory agents and a tissue-targeted delivery system thereof for the treatment of immune-related disorders

Also Published As

Publication number Publication date
WO2010136766A3 (en) 2011-07-07
WO2010136766A2 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
HRP20182135T1 (en) Compositions and methods for treating ige-mediated disorders
HRP20190214T1 (en) Compositions and methods for treating purpura
EP2170309A4 (en) Methods and compositions for treating disorders
IL213526A0 (en) Methods for treating acute myocardial infarctions and associated disorders
EP2429584A4 (en) Methods and compositions for treatment
IL209032A0 (en) Compositions and methods for treating digestive disorders
SMT202300082T1 (en) Methods and compositions for treating complement-associated disorders
EP2461819A4 (en) Methods and compositions for treating trinucleotide repeat disorders
EP2331088A4 (en) Compositions and methods for treating psychiatric disorders
EP2309858A4 (en) Compositions and methods for treating inflammatory disorders
IL215932A0 (en) Compositions and methods for treating burns
EP2271218A4 (en) Use and composition for treating dementia
IL216621A0 (en) New compositions for treating cmt and related disorders
IL210097A0 (en) Compositions and methods for treating unfluenza
ZA201203002B (en) Compositions and methods for treating inflammatory disorders
SG10201408508YA (en) Combination composition useful for treating cardiovascular diseases
EP2485738A4 (en) Compositions and methods for treating obesity
IL218726A0 (en) Methods and pharmaceutical compositions for treating down syndrome
EP2431041A4 (en) Pharmaceutical composition for treating cardiovascular disorder and use thereof
EP2512504A4 (en) Treatment composition and method
IL209947A0 (en) Compositions and methods for treating corneal inflammation
GB2500357B (en) Combination and composition for treating obesity
IL217764A0 (en) Methods and compositions for treating leukemia
EP2462131A4 (en) Compositions and methods for treating beta-amyloid related diseases
GB0915794D0 (en) Screening method and treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)